Pharma BD Deal Intelligence
A $2.8B co-development deal that turned Roche and Alnylam's zilebesiran into a Phase 3-stage cardiovascular asset, with the ~11,000-patient global ZENITH trial dosing its first patient in October 2025 and triggering a $300M milestone — Roche's 60% cost share underwrites the biggest bet yet on RNAi therapy for hypertension.
Alnylam signs a $2.8 billion deal with Roche to advance the Cambridge biotech's injection for high blood pressure, with companies sharing development costs and…
Roche and Alnylam strike a $2.8 billion RNAi deal for zilebesiran, a subcutaneous hypertension treatment that suppresses angiotensinogen production with the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche partnered with Alnylam to co-develop and co-commercialize zilebesiran, an RNAi therapeutic for hypertension in high cardiovascular risk patients, with Roche paying 60% of development costs. The program advanced into the global Phase 3 ZENITH cardiovascular outcomes trial (~11,000 patients, 35 countries); first-patient dosing on Oct 1, 2025 triggered a $300M milestone payment from Roche — the first major milestone realized under the agreement.
Zilebesiran is a Phase 2/3 hepatic AGT-silencing siRNA targeting blood pressure with biannual dosing in high-CV-risk patients; competition spans four MOA classes. RAAS-pathway RNAi/siRNA: zilebesiran is the lead asset in class; there is no approved siRNA for hypertension, so direct MOA competitors are preclinical. Small-molecule antihypertensives (generic backbone): ACE inhibitors (lisinopril, ramipril), ARBs (losartan, valsartan, olmesartan), thiazides, CCBs, and beta-blockers are universally generic and drive single-digit monthly costs, setting a high reimbursement bar for novel agents. Mineralocorticoid receptor antagonists: Kerendia (finerenone, Bayer) is FDA-approved for CKD/T2D-associated CV risk reduction with FIGARO-DKD/FIDELIO-DKD evidence; spironolactone/eplerenone generics anchor resistant hypertension. PCSK9-adjacent RNAi analogs: Leqvio (inclisiran, Novartis, siRNA PCSK9) is the most direct commercial read-through for twice-yearly subcutaneous RNAi uptake in CV prevention, approved for LDL-C reduction with Novartis guiding ~$1B run-rate trajectory. Sotatercept (Winrevair, Merck) anchors pulmonary hypertension. Commercial threat for zilebesiran is payer willingness to fund premium-priced siRNA in a generic-dominated category; KARDIA-3 outcomes data and durability in resistant hypertension will determine formulary positioning against standard-of-care polypharmacy.
Roche partnered with Alnylam for zilebesiran (RNAi for hypertension). Roche pays 60% of development costs.
ZENITH CVOT enrolling ~11,000 patients across 35 countries. Evaluating CV outcomes with biannual dosing.
First-patient dosing in the Phase 3 ZENITH CVOT triggered a $300 million milestone payment from Roche to Alnylam under the 2023 collaboration agreement — the first major milestone realized against the ~$2.49B in potential development/regulatory/commercial milestones.
Phase III CVOT underway. Best-in-disease potential claimed. Phase 2 showed mixed results but Roche committed to Ph3.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Alnylam Pharmaceuticals Inc. (this deal) | 2023 | $2.8B | 72 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2023 deals · Roche Holding AG deals · Cardiovascular deals